Researchers with the Abramson Cancer Center of the University of Pennsylvania, led by Carl June, published results from the first U.S. Phase I trial of CRISPR-Cas9-edited T-cells in humans with advanced cancer.
https://www.pharmalive.com/wp-content/uploads/2020/02/CRISPR-Safe-Cancer-Therapy-BioSpace-2-7-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-02-07 11:59:512020-02-07 14:48:27First Proof CRISPR Can Be Safe in Cancer Therapy